Clinical Trials Logo
  1. Home
  2. Panic Disorder
  3. NCT01680107
  4. Details
NCT01680107 Clinical Trial

D-cycloserine Augmented CBT for Panic Disorder

Panic Disorder Clinical Trial

Official title:
The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT01680107
Other study ID # MRC-01
Secondary ID 2012-003191-39
Status Terminated
Phase Phase 3
First received
Last updated
Start date October 2012
Est. completion date April 30, 2018

Study information
Verified date May 2018
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Recruitment information / eligibility
Status Terminated
Enrollment 33
Est. completion date April 30, 2018
Est. primary completion date October 31, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- clinical diagnosis of panic disorder

- at least moderate agoraphobic avoidance

Exclusion Criteria:

- psychoactive medication last 6 weeks

- exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months

- female participant who is pregnant or breast-feeding

- lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder

- lifetime history of epilepsy or other significant disease or disorder

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• d-cycloserine

• placebo

Behavioral:
• cognitive-behaviour therapy

Locations
Country Name City State
United Kingdom Department of Psychiatry, University of Oxford Oxford

Sponsors (2)
Lead Sponsor Collaborator
University of Oxford Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary self-reported and clinician-rated anxiety and depression measures 6 months
Secondary emotional information processing 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT05868135 - Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT02998502 - The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens N/A
Completed NCT01955954 - Using the Canary Breathing System for Panic Disorder Patients N/A
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00605813 - Special Investigation Of Long Term Use Of Sertraline.
Completed NCT00353470 - Comparison of Psychotherapy Programs to Treat Panic Disorder Phase 3
Completed NCT00167479 - A Study of Risperidone Monotherapy in Bipolar Anxiety Phase 4
Completed NCT00540098 - Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Phase 4
Completed NCT03233542 - The Association Between Physical Sensations and Thinking Styles N/A
Recruiting NCT05967468 - Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT04592536 - A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects Phase 1
Completed NCT00025974 - Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Withdrawn NCT01008371 - Investigation of Neuro-hormonal Mechanisms of Hunger, Fullness and Obesity. N/A